search
Back to results

Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department

Primary Purpose

Migraine

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PMR (Progressive muscle relaxation therapy)
Monitored Usual Care (MUC)
Sponsored by
NYU Langone Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Migraine

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Meets migraine criteria and has 4+ headache days a month

Exclusion Criteria:

  • Patients who have had Cognitive Behavioral Therapy, Biofeedback or other Relaxation Therapy in the past year
  • Cognitive deficit or other physical problem with the potential to interfere with behavioral therapy
  • Alcohol or other substance abuse as determined by self-report or prior documentation in the medical record
  • Unable or unwilling to follow a treatment program that relies on written and audio recorded materials
  • Not having a smartphone

Sites / Locations

  • NYU Langone

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Active Comparator: Progressive Muscle Relaxation (PMR) Therapy

Active Comparator: Monitored Usual Care (MUC)

Arm Description

After the PMR APP is loaded onto the subject's smartphone, the subject will perform PMR in the ED and discuss the optimal time and place to practice PMR at home. All subjects will be asked to keep records of headache occurrence, side effects, compliance, and medication changes on the APP.

Subjects will be given a general education session consisting of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The RC will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that the MUC subjects receive. All subjects will be asked to keep records of headache occurrence, side effects, compliance, and medication changes on the APP.

Outcomes

Primary Outcome Measures

Change in Migraine-Specific Quality of Life Questionnaire-Version 2 (MSQv2) Scores
14-item self-assessment of how migraines affect a patient's life. Items ranked on 6-point Likert scale, where: 1 = None of the time; 2 = A little bit of the time; 3 = Some of the time; 4 = A good bit of time; 5 = Most of the time; and 6 = All of the time. Raw dimension scores are computed as a sum of item responses and rescaled on a 0-100 scale; higher scores indicate better quality of life.
Change in Migraine Disability Assessment Scale (MIDAS) Score
5-item self-administered questionnaire designed to quantify headache-related disability over a 3-month period. For each item, participants indicate the number of days over the past three months that migraine limited their ability to participant in specific activities. The score is the sum responses. Scores are classified as follows: 0 to 5 = Little or no disability (MIDAS Grade I) 6 to 10 = Mild disability (MIDAS Grade II) 11 to 20 = Moderate disability (MIDAS Grade III) 21 and over = Severe disability (MIDAS Grade IV)

Secondary Outcome Measures

Satisfaction Questionnaire Score
9-item questionnaire assessing RELAXaHEAD usability, content, and functionality. Items are ranked on a 5-point Likert scale ranging from 0 (Strongly Disagree) to 4 (Strongly Agree). Total scores range from 0 to 36; higher scores indicate greater satisfaction with the app.
Number of Participants who Experience 50% Decrease in Frequency and/or Intensity of Headaches (HAs)
Measured by electronic HA diary data. HA Frequency reported as number of HAs over the past 30 days, with days starting and ending at midnight. HA Intensity ranked on a 4-point Likert scale: 0 (no HA), 1 (mild HA), 2 (moderate HA), 3 (severe HA).
Number of Days of Acute Medication Use Per Week
Medications included: NSAIDs, acetaminophen, caffeine, aspirin, triptans, barbiturates, opioids, antipsychotics.
Change in Perceived Stress Scale (PSS) Scores
10-item self-assessment measuring perception of stress. Items ranked on 5-point Likert scale, where: 0 = Never; 1 = Almost never; 2 = Sometimes; 3 = Fairly often; and 4 = Very often. Scores on the PSS range from 0-40; higher scores indicate higher perceived stress.
Change in Patient Health Questionnaire-2 (PHQ-2) Scores
2-item questionnaire assessing the frequency of anxiety symptoms over the past two weeks. Items ranked on 4-point Likert scale: 0 (Not at all), 1 (Several days), 2 (More than half the days), 3 (Nearly every day). Scores range from 0-6. Scores greater than 3 indicate major depressive disorder is likely.
Change in General Anxiety Disorder-7 (GAD-7) Scores
7-item questionnaire assessing the frequency of depressed mood and anhedonia over the past two weeks. Items ranked on 4-point Likert scale: 0 (Not at all), 1 (Several days), 2 (More than half the days), 3 (Nearly every day). Scores range from 0-21; where: 0-4: minimal anxiety; 5-9: mild anxiety; 10-14: moderate anxiety; and 15-21: severe anxiety.
Length of Stay in Emergency Department (ED)
Number of Participants who Re-Visit ED within 72-Hours Post-Discharge
Number of Healthcare Visits for Migraine Post-ED Discharge
Number of Participants who Experience Adverse Events
Percentage of Participants who Performed PMR at least 5 Days Per Week
Time Spent Performing PMR
Percentage of Participants with 70% Topiramate Adherence Rate

Full Information

First Posted
December 26, 2019
Last Updated
September 20, 2022
Sponsor
NYU Langone Health
search

1. Study Identification

Unique Protocol Identification Number
NCT04281030
Brief Title
Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department
Official Title
Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
June 30, 2019 (Actual)
Primary Completion Date
March 30, 2022 (Actual)
Study Completion Date
March 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NYU Langone Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a pilot feasibility acceptability study to examine the impact of smartphone-based progressive muscle relaxation (PMR) on migraine quality of life, frequency, intensity, and disability. Feasibility is measured by: a) Proportion of patients who enrolled in the study/were recruited for the study, b) Number of days PMR practiced/week as determined with the backend analytics in the RELAXaHEAD app, c) Minutes/day spent doing PMR, d) Reasons for non-adherence. Acceptability is measured by: a) Satisfaction using Likert scale questions on RELAXaHEAD usability, content, and functionality b) Willingness to repeat a similar treatment intervention in the future (Definitely No/Probably No/Unsure/Probably Yes/ Definitely Yes) c) Attrition. In addition, whether use of electronically based PMR introduced in the ED improves migraine quality of life (MSQv2) at 3 months post ED-discharge (or post enrollment date if recruited post ED discharge) compared to those who are not introduced to PMR will be assessed. All participants (N=85) will complete a migraine quality of life assessment and track their headache frequency and intensity using our smartphone application (app).
Detailed Description
While explaining the study, potential participants will be assured that they will receive all of the medication for their acute headache that they would otherwise receive. Once consented, participants will be randomized to PMR therapy or monitored usual care (MUC). Participants will be told that either group is being tested as an enhancement to the care they typically get in the ED for headache. (At the end, they will be informed which group they were in.) The study team will collect participants' health histories (biologic variables) and baseline data in REDCap, download the app onto subjects' smartphones, and conduct the sessions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
112 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Active Comparator: Progressive Muscle Relaxation (PMR) Therapy
Arm Type
Active Comparator
Arm Description
After the PMR APP is loaded onto the subject's smartphone, the subject will perform PMR in the ED and discuss the optimal time and place to practice PMR at home. All subjects will be asked to keep records of headache occurrence, side effects, compliance, and medication changes on the APP.
Arm Title
Active Comparator: Monitored Usual Care (MUC)
Arm Type
Active Comparator
Arm Description
Subjects will be given a general education session consisting of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The RC will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that the MUC subjects receive. All subjects will be asked to keep records of headache occurrence, side effects, compliance, and medication changes on the APP.
Intervention Type
Behavioral
Intervention Name(s)
PMR (Progressive muscle relaxation therapy)
Intervention Description
Technique for learning to monitor and control the state of muscular tension. The relaxation therapy should take about 20 minutes a day.
Intervention Type
Behavioral
Intervention Name(s)
Monitored Usual Care (MUC)
Intervention Description
General Education Session consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
Primary Outcome Measure Information:
Title
Change in Migraine-Specific Quality of Life Questionnaire-Version 2 (MSQv2) Scores
Description
14-item self-assessment of how migraines affect a patient's life. Items ranked on 6-point Likert scale, where: 1 = None of the time; 2 = A little bit of the time; 3 = Some of the time; 4 = A good bit of time; 5 = Most of the time; and 6 = All of the time. Raw dimension scores are computed as a sum of item responses and rescaled on a 0-100 scale; higher scores indicate better quality of life.
Time Frame
Baseline, Month 3 Post-Discharge
Title
Change in Migraine Disability Assessment Scale (MIDAS) Score
Description
5-item self-administered questionnaire designed to quantify headache-related disability over a 3-month period. For each item, participants indicate the number of days over the past three months that migraine limited their ability to participant in specific activities. The score is the sum responses. Scores are classified as follows: 0 to 5 = Little or no disability (MIDAS Grade I) 6 to 10 = Mild disability (MIDAS Grade II) 11 to 20 = Moderate disability (MIDAS Grade III) 21 and over = Severe disability (MIDAS Grade IV)
Time Frame
Baseline, Month 3 Post-Discharge
Secondary Outcome Measure Information:
Title
Satisfaction Questionnaire Score
Description
9-item questionnaire assessing RELAXaHEAD usability, content, and functionality. Items are ranked on a 5-point Likert scale ranging from 0 (Strongly Disagree) to 4 (Strongly Agree). Total scores range from 0 to 36; higher scores indicate greater satisfaction with the app.
Time Frame
48-Hours Post-Discharge
Title
Number of Participants who Experience 50% Decrease in Frequency and/or Intensity of Headaches (HAs)
Description
Measured by electronic HA diary data. HA Frequency reported as number of HAs over the past 30 days, with days starting and ending at midnight. HA Intensity ranked on a 4-point Likert scale: 0 (no HA), 1 (mild HA), 2 (moderate HA), 3 (severe HA).
Time Frame
Up to Month 3 Post-Discharge
Title
Number of Days of Acute Medication Use Per Week
Description
Medications included: NSAIDs, acetaminophen, caffeine, aspirin, triptans, barbiturates, opioids, antipsychotics.
Time Frame
Up to Month 3 Post-Discharge
Title
Change in Perceived Stress Scale (PSS) Scores
Description
10-item self-assessment measuring perception of stress. Items ranked on 5-point Likert scale, where: 0 = Never; 1 = Almost never; 2 = Sometimes; 3 = Fairly often; and 4 = Very often. Scores on the PSS range from 0-40; higher scores indicate higher perceived stress.
Time Frame
Baseline, Month 3 Post-Discharge
Title
Change in Patient Health Questionnaire-2 (PHQ-2) Scores
Description
2-item questionnaire assessing the frequency of anxiety symptoms over the past two weeks. Items ranked on 4-point Likert scale: 0 (Not at all), 1 (Several days), 2 (More than half the days), 3 (Nearly every day). Scores range from 0-6. Scores greater than 3 indicate major depressive disorder is likely.
Time Frame
Baseline, Month 3 Post-Discharge
Title
Change in General Anxiety Disorder-7 (GAD-7) Scores
Description
7-item questionnaire assessing the frequency of depressed mood and anhedonia over the past two weeks. Items ranked on 4-point Likert scale: 0 (Not at all), 1 (Several days), 2 (More than half the days), 3 (Nearly every day). Scores range from 0-21; where: 0-4: minimal anxiety; 5-9: mild anxiety; 10-14: moderate anxiety; and 15-21: severe anxiety.
Time Frame
Baseline, Month 3 Post-Discharge
Title
Length of Stay in Emergency Department (ED)
Time Frame
Up to Discharge (Average: 2-3 Days)
Title
Number of Participants who Re-Visit ED within 72-Hours Post-Discharge
Time Frame
Up to 72 Hours Post-Discharge
Title
Number of Healthcare Visits for Migraine Post-ED Discharge
Time Frame
Up to Month 3 Post-Discharge
Title
Number of Participants who Experience Adverse Events
Time Frame
Up to Month 3 Post-Discharge
Title
Percentage of Participants who Performed PMR at least 5 Days Per Week
Time Frame
Up to Month 3 Post-Discharge
Title
Time Spent Performing PMR
Time Frame
Up to Month 3 Post-Discharge
Title
Percentage of Participants with 70% Topiramate Adherence Rate
Time Frame
Up to Month 3 Post-Discharge

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Meets migraine criteria and has 4+ headache days a month Exclusion Criteria: Patients who have had Cognitive Behavioral Therapy, Biofeedback or other Relaxation Therapy in the past year Cognitive deficit or other physical problem with the potential to interfere with behavioral therapy Alcohol or other substance abuse as determined by self-report or prior documentation in the medical record Unable or unwilling to follow a treatment program that relies on written and audio recorded materials Not having a smartphone
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mia Minen, MD
Organizational Affiliation
NYU Langone
Official's Role
Principal Investigator
Facility Information:
Facility Name
NYU Langone
City
New York
State/Province
New York
ZIP/Postal Code
10003
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Will be provided upon request

Learn more about this trial

Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department

We'll reach out to this number within 24 hrs